Skip to content

Author

T. I. Qazi

We have 1 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Jul 2026

Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis.

Baxdrostat, particularly at 2 mg, provides clinically meaningful BP reductions, and serious safety outcomes remain entirely comparable to control, which highlights a reassuring safety profile.

B. Khan, Muhammad Yahya, H. Khan et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.